Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, First-in-human, Open-label Trial of the Safety, Efficacy, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Participants With Advanced Solid Tumors

NCT06750185 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06750185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06750185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, First-in-human, Open-label Trial of the Safety, Efficacy, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Participants With Advanced Solid Tumors
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 13, 2025
Completion date
April 30, 2031
Enrollment
248 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor